Ignite Creation Date:
2024-05-06 @ 7:35 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06063681
Status:
RECRUITING
Last Update Posted:
2023-11-22
First Post:
2023-09-23
Brief Title:
A Study of SR-8541A ENPPI Inhibitor in AdvancedMetastatic Solid Tumors
Sponsor:
Stingray Therapeutics
Organization:
Stingray Therapeutics
Study Overview
Official Title:
Phase 1 Dose Escalation Safety Tolerability and Pharmacokinetic Study of SR-8541A ENPP1 Inhibitor Administered Orally as Monotherapy in Subjects With AdvancedMetastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label dose-escalation multi-center phase 1 study evaluating the safety tolerability and pharmacokinetics PK of SR-8541A an ENPP1 inhibitor administered orally as a monotherapy in subjects with solid tumors
Detailed Description:
SR-8541A an ENPP1 inhibitor will be administered orally as a monotherapy to assess safety tolerability and pharmacokinetics PK in subjects with advancedmetastatic solid tumors
Subjects eligible for treatment include those whose disease is refractory to standard therapeutic options or for which there are no standard therapeutic options available
All enrolled patients will orally administer SR-8541A daily Treatment may continue until the subjects disease worsens or another treatment discontinuation criterion is met
Subjects eligible for treatment include those whose disease is refractory to standard therapeutic options or for which there are no standard therapeutic options available
All enrolled patients will orally administer SR-8541A daily Treatment may continue until the subjects disease worsens or another treatment discontinuation criterion is met
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None